Little Journey funding news – London-based Little Journey has Raised £6 Million in Series A Round Funding

Investor of the round

The funding round, led by Par Equity, will help the company grow and expand its mission to transform paediatric healthcare worldwide.

Other investors include Mercia Ventures, the Northern Powerhouse Investment Fund I (NPIF I), Octopus Ventures, Calm/Storm Ventures, and angel investors with healthcare and life sciences experience.

Read Also - Linkup funding news - Paris-based Linkup has Secured €3 Million in Funding

Funding Utilisation

The funding will help Little Journey expand globally, focusing on the US healthcare market. With early supporters already using its services, the company plans to reach more children and families worldwide.

The investment will also improve its products, including content development, data collection, and system compatibility.

These improvements will help healthcare and life science organizations use more data-driven, patient-focused care, improving outcomes for children worldwide. Additionally the funding will strengthen Little Journey’s systems, ensuring its infrastructure and security are ready for global growth.

Chris Evans, Co-Founder & CEO of Little Journey, commented: “Securing this investment allows us to scale our impact across healthcare and life sciences, with a focus on easing the burden of paediatric clinical trials. While legislation like RACE, SPCs, and the ODA has increased study numbers, specialist paediatric knowledge is still lacking in the industry. This has led to lower recruitment, adherence and trial completion rates compared to adult research. Little Journey is uniquely positioned to fill this expertise gap and tackle these challenges to advance global paediatric medicine. With the backing of Par Equity, Mercia Ventures, Octopus Ventures, and our wider investor network, we’re redefining how paediatric clinical trials are run and putting families at the heart of them.”

Sophie Copley, Co-Founder & CPO of Little Journey, said: “We’re ready to take our product capabilities to the next level. Little Journey already tailors support based on age, language, procedure, and trial protocol. With this Series A funding, we will enhance our data capabilities and further globalise our offering, enabling a data-driven, personalised model of care in paediatrics. This will drive impact for our growing international customer base in a patient-centric way. By empowering families with the right knowledge and resources at the right time, we believe we can help build a brighter, healthier future for all children across the globe.”

Little Journey was founded in 2018 by Dr. Chris Evans and Sophie Copley. As an anaesthetist and father, Chris saw firsthand the stress children and families face during hospital visits.

With over a quarter of the world's population being under 18 and paediatric care being under-researched and underfunded, Chris and Sophie teamed up. Sophie brought her expertise in human-centered product design to help tackle this issue.

Elizabeth Young, Investment Manager at Par Equity said: “Healthtech is at the heart of what we do at Par Equity. We are committed to supporting high-growth, impactful health tech companies that have the potential to revolutionise the way that care is delivered. At present, there exists a pressing need for bespoke technologies tailored to children and Little Journey’s innovative approach to paediatric care does just that. We look forward to seeing what’s in store for the future of children’s healthcare and are excited to support Little Journey’s expansion into the US and beyond.”

About Little Journey

Little Journey is a health tech company focused on improving personalised care for children. The platform offers customized support and guidance to help children and their families navigate medical experiences.